Cynata Therapeutics entered into a licensing agreement with Fujifilm Holdings to begin stem cell therapy clinical trials in the U.S. and Japan, according to Nikkei Asian Review.
Here are four things to know:
1. Cynata is developing an induced pluripotent stem cell therapy designed to treat organ or bone marrow transplant complications. The company recently completed the first phase of clinical trials in the U.K. and found the iPS cell treatment to be safe and effective.
2. Cynata's CYP-001 treatment received FDA orphan drug designation.
3. Clinical trials will enter their second phase in 2019. Marketing approval is aimed for 2022 at the latest.
4. Fujifilm holds a 10 percent-plus stake in Cynata. The companies entered into a capital tie-up in 2016.